Clinical Trial

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

Study acronym: ZUMA-22
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this clinical study is test how well the study drug, axicabtagene ciloleucel, works in participants with relapsed/refractory follicular lymphoma
Protocol Amendment History 31 amendments
This ClinicalTrials.gov record has been amended 31 times since 2022-05-09; most recent amendment 2025-10-14.
Status change: Recruiting → Active, Not Recruiting 2025-05-07
Status change: Not Yet Recruiting → Recruiting 2022-07-29
Trial Details
NCT Number NCT05371093
Lead Sponsor Kite, A Gilead Company
Conditions Relapsed/Refractory Follicular Lymphoma
Enrollment 231 participants
Start Date 2022-09-22
Primary Completion 2030-10 (estimated)
Study Completion 2030-10 (estimated)
Updated on ClinicalTrials.gov 2025-10-15